Skip to content
Parallel Bio logo

Parallel Bio

Parallel Bio is a YC Summer 2021 (S21) company. Based in Cambridge, MA, USA; Los Angeles, CA, USA. Team of 9.

  • AI-powered Drug Discovery
  • Biotech

About Parallel Bio

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Parallel Bio builds a human immune system model in vitro, giving pharma and biotech companies a fully human platform to test drugs, vaccines, and immunotherapies before clinical trials. The platform draws on a biobank of patient samples and computational tools to model diverse patient backgrounds, replacing animal testing that has historically produced results that do not translate to humans. Where traditional preclinical work sends compounds into human trials with little predictive power, Parallel Bio's platform maps how those compounds interact with actual human biology.

Business model

Fee-based contracts with pharma and biotech companies to run drug and vaccine testing on the platform.

Go-to-market

Pharma and biotech companies, including large enterprises, engage Parallel Bio directly to run preclinical studies through a sales-led model.

From the Y Combinator listing

How Parallel Bio describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Using the immune system to cure disease

Parallel Bio created a human 'immune system in a dish' to discover drugs and immunotherapies more likely to work in patients. Our platform has all of the same elements as a human immune system, meaning you can test drugs and vaccines as if you were testing them in actual patients from the start. The biggest reason why 95% of new drugs fail is that they were tested in mice - but with our human platform, pharma companies will know which drugs will successfully treat patients, speeding up the process and reducing the cost. To date our platform has successfully been used to test 12 drugs, and vaccines against 8 different diseases. The company is founded by Robert DiFazio, a former Stanford R&D director with a PhD in immunology, and Juliana Hilliard, a former System1 Biosciences R&D lead with an MSc in bioengineering, both of whom have led drug discovery programs for years.

Facts

Industry
Healthcare / Healthcare -> Drug Discovery and Delivery
Location
Cambridge, MA, USA; Los Angeles, CA, USA
Team size
9
Status
Active
Stage
Early

Founders (2)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works